07/12/2017 12:45:00

Beleave Signs Brand Licensing Agreement with Kevin Smith & Jason Mewes

TORONTO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. ("Beleave" or the "Company") (CSE:BE) (OTCQX:BLEVF) is pleased to announce that it has entered into a Brand Licensing Agreement with Kevin Smith and Jason Mewes, better known as their onscreen characters, Jay and Silent Bob.  Under the agreement the Company, in partnership with Kevin Smith and Jason Mewes, will be developing various proprietary strains geared towards the recreational market which will be available under the Beleave Kannabis brand.

“We are excited to welcome Kevin and Jason to our team, their passion for the industry is something that resonates with us,” commented Beleave CEO Andrew Wnek. “We look forward to working together to explore unique, outside the box business opportunities over the coming years.”

Kevin Smith is a filmmaker, actor, comic book writer, author, and podcaster well known for his comedy film Clerks (1994), which he wrote, directed, co-produced, and acted in as the character Silent Bob.  Jay and Silent Bob have appeared in Smith's follow-up films Mallrats, Chasing Amy, Dogma, and Jay and Silent Bob Strike Back.

“It’s no secret that I’m a fan of cannabis, it helps me sleep at night and keeps my blood pressure down.  I’ve seen cannabis drastically improve the lives of some of the closest people in my life, and believe it could be a viable alternative to the use of traditional pain killers,” said Kevin Smith.  “This culminating with the changing laws and perception surrounding cannabis has me very excited to team up with Beleave, a group I believe to be one of the most innovative in the Canadian cannabis space.”

“It’s hard for me to argue against the potential benefits that Medical Cannabis can bring.  Much like the Beleave team I have a personal connection to the remedy. Now that Canada is on the verge of legalizing cannabis, I am looking forward to the opportunity to work with the scientifically focused and forward thinking team at Beleave, there’s no telling what we can dream up together,” said Jason Mewes.

Jason Mewes, is perhaps best known as the vocal half of the on-screen comedic duo, Jay and Silent Bob. Mewes’ has reprised his role as celebrated character, “Jay,” in a number of hit films. Mewes has captured audiences with rebellious banter against his unspoken other half and long-time friend, Kevin Smith (Silent Bob).

“Kevin and Jay played the quintessential stoners in a bunch of 90’s comedies, but are serious about the benefits of the cannabis lifestyle,” continued Beleave CEO Andrew Wnek, “It’s definitely going to be fun watching them take an active role in the space while developing strains together.”

About Beleave

Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located in Hamilton, Ontario.

For further information please contact:

Sebastian de Kloet

Phone: (905) 979 - 5173 

Email: sebastian@beleave.com

beleave.com

Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. These risks and uncertainties include, but are not limited to, the Company's ability to satisfy the conditions associated with its cultivation license, the Company's ability to obtain a sales license and the related timing considerations, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on

www.sedar.com

.

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
13 Dec
FING-B
Hvem tør efterhånden investere på børsen, med dette ufatteligt ødelæggende shorting og naked-short v..
30
10 Dec
VWS
Der er simpelhen så meget støj i marked omkring Vestas. Prøv at vurdere disse få tal, og din beslutn..
26
14 Dec
VELO
Faldt lige over denne artikel, som er frigivet 20/11 2017.... Asertaa-studiet med dens konklusioner ..
20
10 Dec
VELO
  @djks Tak for dine altid velovervejede indlæg, som er af stor betydning for debatten, idet man som..
18
12 Dec
BAVA
Prøver du at dække dig ind under Bavarian for at undgå at vi snakker om dine enorme tab i Matas og R..
17
10 Dec
NOVO-B
En julehilsen fra alpehue, og  et "Olympic" tillykke til Novo, dens aktionærer og verdens diabetespa..
17
13 Dec
GEN
Han har ingen model. Det er noget han altid skriver. Det er som i SKAT - der mangler ikke folk i Ska..
15
14 Dec
VWS
Citat: »Vores ordreindgang voksede 50 pct. i det seneste kvartal. Der er intet galt med vores salg, ..
14
12 Dec
GEN
Minder lige om denne fra d. 21.11.2017:http://medwatch.dk/Medicinal___Biotek/article10047753.ece   "..
14
09 Dec
VWS
Lad mig prøve vs. Vestas at tage "prispres" fra en anden side, for der er også prispres i USA !!   M..
14

Alliance Trust PLC : Transaction in Own Shares

15/12/2017 07:00:16
15 December 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 14 December 2017 the Company purchased for cancellation 184,000 ordinary shares of 2.5p each at a price of 737.0383p per share.  Therefore, the total number of voting rights in the Company is now 347,592,156.    The above figure (347,592,156) may be used by sha..

Form 8.3 - Tesco PLC

14/12/2017 11:47:54
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Jupiter Asset Management (b) Owner or controlle..

Dimensional Fund Advisors Ltd. : Form 8.3 - Tesco Plc - Ordinary shares

14/12/2017 10:47:13
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Voip-Pal.com, Inc. Discusses the Global Potential of its RBR Parent Patent
2
Make Christmas Personal with New Celebrity Video Ecards from American Greetings
3
Impac Mortgage Holdings, Inc. Announces Hire of Rian Furey to lead its Consumer Direct Retail Channel
4
Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae
5
Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
15 December 2017 08:19:02
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171124.1 - EUROWEB4 - 2017-12-15 09:19:02 - 2017-12-15 08:19:02 - 1000 - Website: OKAY